Ongoing challenges of a global international patient assistance program

Annals of Oncology

Volumn 17, Issue SUPPL. 8, 2006, Pages

  Lassarat, Stephanie ^a,c   Jootar, S ^b  

^a Novartis Oncology   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic myelogenous leukemia; Developing countries; Gastrointestinal stromal tumours; Glivec; Patient access

Indexed keywords

ALPHA INTERFERON; CYTARABINE; HYDROXYUREA; IMATINIB;

ARTICLE; AWARENESS; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CULTURAL FACTOR; DRUG COST; DRUG MECHANISM; GASTROINTESTINAL STROMAL TUMOR; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE NEED; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; RESOURCE MANAGEMENT;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; DEVELOPING COUNTRIES; GASTROINTESTINAL STROMAL TUMORS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONAL COOPERATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC; NEOPLASMS; PIPERAZINES; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; PUBLIC HEALTH; PYRIMIDINES; THAILAND; WORLD HEALTH;

EID: 33745608999     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl987     Document Type: Article

References (9)

1. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
2. Hahn EA, Glendenning GA. Quality of life on imatinib. Semin Hematol 2003; 40: 31-36.
3. Simonsson B. Beneficial effects of cytogenetic and molecular response on long-term outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib: Update from the IRIS study. American Society of Hematology Annual Meeting Abstracts 2005; 106: Abstr 166.
4. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002; 347: 472-480.
5. Blanke C, Joensuu H, Demetri G et al. Outcome of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate: Four-year follow-up of a phase II randomized trial. Gastrointestinal Cancers Symposium Abstracts 2006. Abstr 7.
6. Sener SF, Grey N. The global burden of cancer. J Surg Oncol 2005; 92: 1-3.
7. World Health Organization. Cancer Prevention and Control. Report to the Secretariat by the 58th World Health Assembly. (2005). [Online]. http://www.who.int/mediacentre/news/releases/2003/pr27/en/ (Date last accessed: January 10, 2006).
8. World Health Organization. The World Health Report 2000: Health systems: Improving performance. Geneva, Switzerland: WHO 2000.
9. World Health Organisation. Country Health Profile: Thailand. [Online]. http://w3.whosea.org/cntryhealth/thalland/thalland.pdf (Date last accessed: 15 February 2006).